86 related articles for article (PubMed ID: 15458519)
1. Long-term alpha interferon treatment is effective on anaemia and significantly reduces iron overload in congenital dyserythropoiesis type I.
Lavabre-Bertrand T; Ramos J; Delfour C; Henry L; Guiraud I; Carillo S; Wagner A; Bureau JP; Blanc P
Eur J Haematol; 2004 Nov; 73(5):380-3. PubMed ID: 15458519
[TBL] [Abstract][Full Text] [Related]
2. Congenital dyserythropoietic anemia type I with bone abnormalities, mutations of the CDAN I gene, and significant responsiveness to alpha-interferon therapy.
Goede JS; Benz R; Fehr J; Schwarz K; Heimpel H
Ann Hematol; 2006 Sep; 85(9):591-5. PubMed ID: 16767397
[TBL] [Abstract][Full Text] [Related]
3. Successful management of congenital dyserythropoietic anemia type I with interferon alpha in a child.
Yarali N; Fişgin T; Duru F; Atilla P; Müftüoğlu SF; Kaymaz SF
Pediatr Hematol Oncol; 2005 Jun; 22(4):265-70. PubMed ID: 16020112
[TBL] [Abstract][Full Text] [Related]
4. Interferon therapy in congenital dyserythropoietic anemia type I/II.
Marwaha RK; Bansal D; Trehan A; Garewal G
Pediatr Hematol Oncol; 2005 Mar; 22(2):133-8. PubMed ID: 15804998
[TBL] [Abstract][Full Text] [Related]
5. Antioxidant therapy for severe cardiac failure induced by iron overload secondary to dyserythropoietic anaemia.
van der Merwe J; Leong JY; Kaye D; Opat S; Bergin PJ; Taylor AJ; Rosenfeldt F
Heart Lung Circ; 2007 Oct; 16(5):394-7. PubMed ID: 17314073
[TBL] [Abstract][Full Text] [Related]
6. Interferon alpha is an effective therapy for congenital dyserythropoietic anaemia type I.
Shamseddine A; Taher A; Jaafar H; Haidar JH; Nasr R; Arzoumanian V; Salem Z; Bazarbachi A
Eur J Haematol; 2000 Sep; 65(3):207-9. PubMed ID: 11007058
[TBL] [Abstract][Full Text] [Related]
7. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors use suppresses iron absorption in congenital dyserythropoietic anemia.
Shalev H; Quider AA; Harosh MB; Kapelushnik J
Pediatr Hematol Oncol; 2016; 33(7-8):457-461. PubMed ID: 27960647
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of iron overload with phlebotomies in two siblings with congenital dyserythropoietic anemia--type II (CDA-II).
Chrobák L
Acta Medica (Hradec Kralove); 2006; 49(3):193-5. PubMed ID: 17117609
[TBL] [Abstract][Full Text] [Related]
10. Congenital dyserythropoietic anemia, type 1, in a polynesian patient: response to interferon alpha2b.
Roda L; Pasche J; Fournier A; Terorotua V; Wickramasinghe SN; Tamary H; Schischmanoff PO; Tchernia G; Delaunay J
J Pediatr Hematol Oncol; 2002; 24(6):503-6. PubMed ID: 12218603
[TBL] [Abstract][Full Text] [Related]
11. Treatment of transfusion-dependent congenital dyserythropoietic anemia Type I patients with pegylated interferon alpha-2a.
Abu-Quider A; Asleh M; Shalev H; Fruchtman Y; Ben-Harosh M; Beck G; Kapelushnik J
Eur J Haematol; 2020 Aug; 105(2):216-222. PubMed ID: 32302424
[TBL] [Abstract][Full Text] [Related]
12. [Congenital dyserythropoietic anemia--type II (CDA-II) in 3 siblings with long-term follow up and iron overload].
Chrobák L; Hůlek P; Nozicka J
Acta Medica (Hradec Kralove) Suppl; 2004; 47(1):29-33. PubMed ID: 15745056
[TBL] [Abstract][Full Text] [Related]
13. Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels.
Karam LB; Disco D; Jackson SM; Lewin D; McKie V; Baker RD; Baker SS; Laver JH; Nietert PJ; Abboud MR
Pediatr Blood Cancer; 2008 Jan; 50(1):62-5. PubMed ID: 17457853
[TBL] [Abstract][Full Text] [Related]
14. The pathogenesis, diagnosis and management of congenital dyserythropoietic anaemia type I.
Roy NBA; Babbs C
Br J Haematol; 2019 May; 185(3):436-449. PubMed ID: 30836435
[TBL] [Abstract][Full Text] [Related]
15. Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies.
Kim YR; Kim JS; Cheong JW; Song JW; Min YH
Acta Haematol; 2008; 120(3):182-9. PubMed ID: 19129689
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors.
Majhail NS; DeFor T; Lazarus HM; Burns LJ
Biol Blood Marrow Transplant; 2008 Jul; 14(7):790-4. PubMed ID: 18541198
[TBL] [Abstract][Full Text] [Related]
17. [Successful treatment of congenital dyserythropoietic anemia type I with long-term administration of deferoxamine].
Miyazawa K; Yoshikawa O; Takakuwa Y; Tuda A; Ohtaka M; Lin KY; Iguchi Y; Naruto M; Kondo M; Toyama K
Rinsho Ketsueki; 1988 Sep; 29(9):1454-9. PubMed ID: 3063858
[No Abstract] [Full Text] [Related]
18. Severe congenital dyserythropoietic anaemia type I: prenatal management, transfusion support and alpha-interferon therapy.
Parez N; Dommergues M; Zupan V; Chambost H; Fieschi JB; Delaunay J; Miélot F; Cramer EM; Dommergues JP; Wickramasinghe SN; Tchernia G
Br J Haematol; 2000 Aug; 110(2):420-3. PubMed ID: 10971401
[TBL] [Abstract][Full Text] [Related]
19. The challenges of using serum ferritin to guide i.v. iron treatment practices in patients on hemodialysis with anemia.
Easom A
Nephrol Nurs J; 2006; 33(5):543-51; quiz 552-3. PubMed ID: 17044438
[TBL] [Abstract][Full Text] [Related]
20. Successful management of transfusion-dependent congenital dyserythropoietic anemia type 1b with interferon alfa-2a.
Rathe M; Møller MB; Greisen PW; Fisker N
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29049846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
